antibody

Mouse Anti-Rat Podoplanin

MBS690143

0.1 mg

345 USD

monoclonal

mouse

nonconjugated

[IgG1, LF3(B7)D5B3]

western blot, immunohistochemistry, immunocytochemistry

Antibody

Mouse Anti-Rat Podoplanin

[Podoplanin]

[Anti-rat Podoplanin (#LF3(B7)D5B3); Glycoprotein 36; GP36; T1-alpha; PA2.26 antigen]

[podoplanin; Podoplanin; podoplanin; T1A; RTI140; glycoprotein 38; E11 antigen epitope; type I cell 40 kDa protein; epithelial cell surface transmembrane protein antigen; pulmonary type I alveolar epithelial cell transmembrane differentiation marker; podoplanin; E11 antigen epitope; Glycoprotein 38; Gp38; OTS-8; RTI140; T1-alpha; T1A; Type I cell 40 kDa protein]

[Pdpn; Pdpn; E11; Gp38; OTS-8; RTI40; T1-alpha; Gp38; Ots8; Gp38; T1A]

PDPN_RAT

Monoclonal

IgG

[IgG1, LF3(B7)D5B3]

Mouse

ND

166

Protein G purified

Lyophilized

The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 degree C. Frozen aliquots are stable for at least 6 months when stored at -20 degree C.

Western Blot, IHC/IF

IF/IHC: Cryo section (acetone fixed). Western Blot: Use at 1-5 ug/ml

Testing Data

Testing Data #2

Testing Data #3

Immunofluorescence

Rat cardiac lymphatic microvessels, labeled with a monoclonal antibody against rat Podoplanin (green) [left panel] and a polyclonal antibody against mouse LYVE-1 [Cat# MBS691451; right panel] (red). Image wasobtained at 20x magnification on a Zeiss fluorescence microscope. Scale bar = 50 um. The used protocol in short was: 1. Blockage of nonspecific binding; 2. Incubation with primary abs : anti-mouse Lyve1 (1:1000) and mouse anti- Podoplanin (1:400) for 60 min at RT; 3. Incubation with secondary abs: Donkey anti-rabbit Cy3 and Donkey anti-mouse FITC, 30 min at RT; 4. Mounting in DAPI-containing medium for cell nuclei labeling.

Immunogen: membrane protein fraction of isolated rat glomeruli. Preparation: Monoclonal antibodies were produced with the help of BALB/c mice using a membrane protein fraction of isolated rat glomeruli as the immunizing antigen.

Buffer: PBS. Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.

Podoplanin, also known as glycoprotein 36 (gp36), PA2.26 antigen, T1-alpha (T1A), and aggrus, is a 36 kDa type I transmembrane sialoglycoprotein and member of the Podoplanin family. Podoplanin has three potential splice variants, the longest of which is represented by a 238 amino acid precursor. It contains an undefined signal sequence, a 22 aa transmembrane segment (aa 207-228) and a short cytoplasmic tail (aa 229-238). The cytoplasmic tail contains putative sites for protein kinase C phosphorylation. There are two potential alternate start sites at Met 77 (Swiss Prot #: Q86YL7) and Met 119 (EAW51692) that generate short forms. The 162 aa short form Podoplanin precursor shares 47% aa identity with mouse Podoplanin. Podoplanin is expressed on glomerular epithelial cells (podocytes), type I lung alveolar cells, lymphatic endothelial cells, and numerous tumors, including colorectal tumors, squamous cell carcinomas, testicular seminoma, and brain tumors. One study showshigh expression of Podoplanin mRNA in placenta, lung, skeletal muscle, and heart, and weaker levels in brain, kidney, and liver. Podoplanin is the ligand for C-type lectin-like receptor 2 (CLEC-2). Their association is dependent on sialic acid on O-glycans of Podoplanin. Through its association with CLEC-2, Podoplanin induces platelet aggregation and tumor metastasis. Podoplanin is also necessary for lymphatic vessel formation, normal lung cell proliferation and alveolus formation at birth.

1. Zimmer et al, Biochem J 341:277, 1999 2. KatsueInoue et al, J Biol Chem 282:25993, 2007 3. Kato et al, J Biol Chem 278:51599, 2003 4. Schacht et al, Am J Pathol 166:913, 2005 5. Breiteneder-Geleff et al, Am J Pathol 151:1141, 1997 6. Kato et al, Tumour Biol 26:195, 2005 7. Kato et al, Oncogene 23:8552, 2004 8. Mishima et al, Acta Neuropathol 111:563, 2006 9. Mishima et al, Acta Neuropathol 111:483, 2006 10. Kato et al, Biochem Biophys Res Commun 349:1301, 2006

9506743

NP_062231.1

NM_019358.1

Q64294

17,579 Da

membrane glycoprotein that may function in lung development [RGD, Feb 2006]

Function: May be involved in cell migration and/or actin cytoskeleton organization. When expressed in keratinocytes, induces changes in cell morphology with transfected cells showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion. Required for normal lung cell proliferation and alveolus formation at birth. Induces platelet aggregation. Does not have any effect on folic acid or amino acid transport. Does not function as a water channel or as a regulator of aquaporin-type water channels . By similarity. Subcellular location: Membrane; Single-pass type I membrane protein. Cell projection lamellipodium membrane; Single-pass type I membrane protein. Cell projection filopodium membrane; Single-pass type I membrane protein. Cell projection microvillus membrane; Single-pass type I membrane protein. Cell projection ruffle membrane; Single-pass type I membrane protein. Note: Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles. Ref.3. Tissue specificity: In adult kidney, expressed on the urinary surface and foot processes of podocytes and in parietal epithelial cells of Bowman's capsule where it is localized to luminal surfaces. In lung, expressed exclusively on luminal surfaces of type I alveolar epithelial cells and pleural mesothelial cells. Not expressed in type II alveolar cells. In bone, expressed in osteocytes and osteoblasts. In spleen, liver, stomach and intestine, expressed in mesoepithelium. Also expressed in thymic epithelial cells, choroid plexus and leptomeninges. Ref.3 Ref.4. Developmental stage: In newborn kidney, not detected at the vesicle stage. First detected in S-shaped bodies. Ref.3. Post-translational modification: Extensively O-glycosylated. Contains sialic acid residues. O-glycosylation is necessary for platelet aggregation activity. Ref.6The N-terminus is blocked. Miscellaneous: Down-regulated in puromycin aminonucleoside nephrosis (PAN). Sequence similarities: Belongs to the podoplanin family.

0.1 mg

345 USD